Patents by Inventor Robert K. Hamatake

Robert K. Hamatake has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HBV antisense inhibitors
    Patent number: 8598334
    Abstract: Antisense oligomers useful for modulating hepatitis B virus infections, and for the treatment of hepatitis B virus (HBV) and hepatitis B virus-related conditions in animals including humans. More particularly, antisense oligomers with modified nucleotides for treatment of HBV in animals, more particularly antisense oligomers comprising 2?O-4?C-methylene-bridged sugars, or nucleotides with other 2?O-4?C bridged sugars, also known as locked nucleic acids (LNA), for treatment of HBV in animals, and more particularly for treatment of HBV in humans.
    Type: Grant
    Filed: October 15, 2010
    Date of Patent: December 3, 2013
    Assignee: Glaxo Group Limited
    Inventor: Robert K. Hamatake
  • MODULATION OF HEPATITIS B VIRUS (HBV) EXPRESSION
    Publication number: 20120295961
    Abstract: Disclosed herein are antisense compounds and methods for decreasing HBV mRNA, DNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate HBV-related diseases, disorders or conditions.
    Type: Application
    Filed: April 20, 2012
    Publication date: November 22, 2012
    Inventors: ERIC E. SWAYZE, ROBERT K. HAMATAKE
  • HBV ANTISENSE INHIBITORS
    Publication number: 20120207709
    Abstract: Antisense oligomers useful for modulating hepatitis B virus infections, and for the treatment of hepatitis B virus (HBV) and hepatitis B virus-related conditions in animals including humans. More particularly, antisense oligomers with modified nucleotides for treatment of HBV in animals, more particularly antisense oligomers comprising 2?O-4?C-methylene-bridged sugars, or nucleotides with other 2?O-4?C bridged sugars, also known as locked nucleic acids (LNA), for treatment of HBV in animals, and more particularly for treatment of HBV in humans.
    Type: Application
    Filed: October 15, 2010
    Publication date: August 16, 2012
    Inventor: Robert K. Hamatake
  • Antiviral peptides
    Patent number: 5859187
    Abstract: Inhibition of UL42 stimulation of herpesvirus DNA polymerase activity is exhibited by novel compounds of the formulasW'--A.sub.1 --A.sub.2 --A.sub.3 --A.sub.4 --A.sub.5 --A.sub.6 --A.sub.7 --A.sub.8 --A.sub.9 --A.sub.10 --A.sub.11 --X ?SEQ. ID NO: 1!andY'--A.sub.12 --A.sub.13 --A.sub.14 --A.sub.15 --A.sub.16 --A.sub.17 --Z ?SEQ. ID NO: 2!that are useful as antiviral agents.
    Type: Grant
    Filed: January 29, 1992
    Date of Patent: January 12, 1999
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: James T. Matthews, Katerina Leftheris, Robert K. Hamatake, John T. Stevens, Mary L. Haffey